Novavax Inc vs Utilities Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Utilities Select Sector SPDR Fund trades at $44.98. The key difference: Utilities Select Sector SPDR Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | XLU | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | — |
52-Week High | $11.19 | $47.73 |
52-Week Low | $6.22 | $41.31 |
Enterprise Value | $800.50M | — |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
XLU trades at $44.93, down 0.51% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The ETF benefits from strong AI-driven power demand tailwinds, positioning utilities as growth plays amid sector rotation. Recent news highlights its role in the AI infrastructure boom, with defensive characteristics attracting investors during tech volatility.
Outlook is positive due to structural electricity demand growth from AI data centers, though regulatory risks and execution challenges remain. The ETF offers stable dividends and exposure to regulated utilities, with Wall Street sentiment leaning bullish on earnings potential. Key risks include grid capacity constraints and interest rate sensitivity.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →